Regeneron Pharmaceuticals is a leading biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines. The company was founded in 1988 by Leonard Schleifer, a neurologist, and George Yancopoulos, a biochemist, with the vision of using advanced science and technology to address unmet medical needs.
Regeneron's core mission is to develop breakthrough therapies that can significantly improve patients' lives. The company is known for its cutting-edge research and development efforts in the fields of immunology, oncology, ophthalmology, and rare diseases.
One of Regeneron's most notable achievements is its proprietary VelociSuite® technology, which accelerates the drug discovery and development process. This platform allows scientists to generate genetically modified animals to study diseases and potential therapies more effectively.
Regeneron's flagship product is EYLEA® (aflibercept), an FDA-approved treatment for several eye conditions, including wet age-related macular degeneration (AMD) and diabetic macular edema. The company has also gained recognition for its role in developing and supplying COVID-19 treatments, including the monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab).
Regeneron has established strategic partnerships with various pharmaceutical companies and research institutions to advance its drug development programs. Notably, the company collaborated with Sanofi to co-develop and commercialize certain therapies.
Regeneron has received numerous awards and recognition for its contributions to the biotechnology and pharmaceutical industries. The company's commitment to scientific excellence and patient-focused innovation has earned it a strong reputation among peers and healthcare professionals.
The company's state-of-the-art research and development facilities in Tarrytown, New York, are equipped with advanced technologies and a team of dedicated scientists and researchers. Regeneron's investments in cutting-edge research and its robust pipeline of potential therapies position it as a major player in the biopharmaceutical industry.